SG11201908994RA - Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy - Google Patents

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Info

Publication number
SG11201908994RA
SG11201908994RA SG11201908994RA SG11201908994RA SG 11201908994R A SG11201908994R A SG 11201908994RA SG 11201908994R A SG11201908994R A SG 11201908994RA SG 11201908994R A SG11201908994R A SG 11201908994RA
Authority
SG
Singapore
Prior art keywords
international
tils
october
pct
processes
Prior art date
Application number
Inventor
Seth Wardell
James Bender
Michael Lotze
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201908994R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of SG11201908994RA publication Critical patent/SG11201908994RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT onion °nolo OH 1101 H mum° oimIE (10) International Publication Number WO 2018/182817 Al (51) International Patent Classification: C12N 5/0783 (2010.01) C12M 1/04 (2006.01) (21) International Application Number: PCT/US2018/012633 (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/478,506 62/539,410 62/548,306 62/554,538 62/559,374 62/567,121 62/577,655 62/582,874 62/596,374 05 January 2018 (05.01.2018) English English Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 29 March 2017 (29.03.2017) US 31 July 2017 (31.07.2017) US 21 August 2017 (21.08.2017) US 05 September 2017 (05.09.2017) US 15 September 2017 (15.09.2017) US 02 October 2017 (02.10.2017) US 26 October 2017 (26.10.2017) US 07 November 2017 (07.11.2017) US 08 December 2017 (08.12.2017) US Applicant: IOVANCE BIOTHERAPEUTICS, INC. [US/US]; 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). Inventors; and Applicants: WARDELL, Seth [US/US]; 30204 USF Hol- ly Drive, Tampa, FL 33620 (US). BENDER, James [US/US]; 3 Cloverdale, Rancho Santa Margarita, CA 92688 (US). LOTZE, Michael, T. [US/US]; 5134 Westminster Place, Pittsburgh, PA 15232 (US). Agent: MACDOUGALL, Christina, A. et al.; Morgan, Lewis, & Bockius LLP, One Market, Spear Tower, San Fan- cisco, CA 94105 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, N GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, co co (54) Title: PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IM- MUNOTHERAPY 00 (57) : The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic O populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as C well as decreased costs. Such TILs fmd use in therapeutic treatment regimens.
SG11201908994R 2017-03-29 2018-01-05 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy SG11201908994RA (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762478506P 2017-03-29 2017-03-29
US201762539410P 2017-07-31 2017-07-31
US201762548306P 2017-08-21 2017-08-21
US201762554538P 2017-09-05 2017-09-05
US201762559374P 2017-09-15 2017-09-15
US201762567121P 2017-10-02 2017-10-02
US201762577655P 2017-10-26 2017-10-26
US201762582874P 2017-11-07 2017-11-07
US201762596374P 2017-12-08 2017-12-08
PCT/US2018/012633 WO2018182817A1 (en) 2017-03-29 2018-01-05 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Publications (1)

Publication Number Publication Date
SG11201908994RA true SG11201908994RA (en) 2019-10-30

Family

ID=61569356

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908994R SG11201908994RA (en) 2017-03-29 2018-01-05 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Country Status (35)

Country Link
US (60) US10894063B2 (en)
EP (6) EP3910055A1 (en)
JP (6) JP7169291B2 (en)
KR (2) KR20240114787A (en)
CN (1) CN110785486A (en)
AU (2) AU2018243355B2 (en)
BR (1) BR112019020326A2 (en)
CA (1) CA3057975A1 (en)
CL (2) CL2019002769A1 (en)
CO (1) CO2019011995A2 (en)
CR (1) CR20190487A (en)
CY (1) CY1124136T1 (en)
DK (3) DK3730608T3 (en)
EC (1) ECSP19077884A (en)
ES (3) ES2874335T3 (en)
FI (2) FI3730608T3 (en)
HR (3) HRP20250068T1 (en)
HU (3) HUE054829T2 (en)
IL (2) IL305198A (en)
JO (1) JOP20190224A1 (en)
LT (3) LT3722415T (en)
MA (2) MA68598B1 (en)
MD (3) MD3601533T2 (en)
MX (2) MX2019011768A (en)
PE (1) PE20191841A1 (en)
PH (1) PH12019502247A1 (en)
PL (3) PL3722415T3 (en)
PT (3) PT3722415T (en)
RS (3) RS66400B1 (en)
SG (1) SG11201908994RA (en)
SI (3) SI3601533T1 (en)
SM (3) SMT202500027T1 (en)
TN (1) TN2019000273A1 (en)
TW (1) TWI799402B (en)
WO (1) WO2018182817A1 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2771251T3 (en) 2013-03-01 2020-07-06 Us Health Methods of producing enriched populations of tumor-reactive T cells from peripheral blood
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
MX2019004707A (en) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc RE-STIMULATION OF CRYOCONSERVED INFILTRATING TUMOR LYMPHOCYTES.
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
BR112019018915A2 (en) 2017-03-15 2020-04-14 Pandion Therapeutics Inc targeted immunotolerance
US11254913B1 (en) * 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Operations for the production of tumor-infiltrating lymphocytes and their use in immunotherapy
CN111010866A (en) 2017-05-24 2020-04-14 潘迪恩治疗公司 Targeted immune tolerance
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP7557367B2 (en) * 2017-11-17 2024-09-27 アイオバンス バイオセラピューティクス，インコーポレイテッド TIL expansion from fine needle aspirates and small biopsies
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112020013848A2 (en) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019178420A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
SG11202009170UA (en) * 2018-03-29 2020-10-29 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN112368003A (en) 2018-04-27 2021-02-12 艾欧凡斯生物治疗公司 Gene editing of tumor-infiltrating lymphocytes and their use in immunotherapy
WO2019217753A1 (en) * 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
BR122023024103A2 (en) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF BTK VIA THE UBIQUITIN PROTEOsome PATHWAY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND THEIR USES
JOP20210094A1 (en) 2018-11-05 2023-01-30 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3877512A2 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
BR112021008549A2 (en) * 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
BR112021008461A2 (en) * 2018-11-08 2021-08-03 Gammadelta Therapeutics Ltd methods for isolating and expanding cells
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020146740A1 (en) 2019-01-10 2020-07-16 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP7640047B2 (en) * 2019-07-10 2025-03-05 国立研究開発法人国立がん研究センター Specific marker for identifying T cells specifically attacking cancer cells
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
US20220273717A1 (en) * 2019-08-12 2022-09-01 Bellicum Pharmaceuticals, Inc. Improved formulations for immune cells
MX2022001781A (en) 2019-08-19 2022-03-11 Univ Basel Cell therapy methods.
AU2020352609A1 (en) 2019-09-24 2022-03-31 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
JP2022553389A (en) * 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド Gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy
EP4570320A3 (en) 2019-12-04 2025-08-27 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3161104A1 (en) * 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
JP7303391B2 (en) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド Biased IL2 muteins, methods, and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US12159700B2 (en) * 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
KR20230002554A (en) 2020-04-28 2023-01-05 아킬레스 테라퓨틱스 유케이 리미티드 T cell therapy
AU2021265797A1 (en) 2020-04-28 2022-12-08 Lyell Immunopharma, Inc. Methods for culturing cells
JP2023524032A (en) * 2020-04-30 2023-06-08 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート Cancer immunotherapy using tumor-infiltrating lymphocytes based on neoantigen information
TW202208616A (en) * 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 Selection of improved tumor reactive t-cells
US20230172987A1 (en) 2020-05-04 2023-06-08 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
WO2021239083A1 (en) * 2020-05-29 2021-12-02 上海君赛生物科技有限公司 Seed cell medium of tumor-infiltrating lymphocyte and application thereof
CN111876381A (en) * 2020-07-22 2020-11-03 中美冠科生物技术（太仓）有限公司 T cell model and application thereof in-vitro human PD-1 antibody efficacy evaluation
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023550490A (en) 2020-11-23 2023-12-01 ライエル・イミュノファーマ・インコーポレイテッド Methods for culturing immune cells
KR20230135571A (en) 2020-11-25 2023-09-25 상하이 준셀 테라퓨틱스 컴퍼니 리미티드 Tumor-infiltrating lymphocyte medium and its applications
WO2022111573A1 (en) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 Pharmaceutical composition for enhancing cell killing, and use thereof
TW202241468A (en) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
JP2024500748A (en) * 2020-12-18 2024-01-10 インスティル バイオ （ユーケイ） リミテッド Treatment of tumor-infiltrating lymphocytes
WO2022130017A2 (en) * 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
US20240110152A1 (en) 2020-12-31 2024-04-04 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
CN114686430A (en) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 A kind of method for preparing TIL
US20240052309A1 (en) * 2021-01-04 2024-02-15 Thyas Co. Ltd. Method for producing regenerated t cell via ips cell
CA3206549A1 (en) * 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
AU2022226660A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
EP4308691A1 (en) * 2021-03-19 2024-01-24 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
IL306072A (en) 2021-03-25 2023-11-01 Iovance Biotherapeutics Inc Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
JP2024515189A (en) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy - Patents.com
AR125461A1 (en) 2021-04-27 2023-07-19 Takeda Pharmaceuticals Co RECOMBINANT ANTIGEN PRESENTING CELLS
EP4340850A1 (en) 2021-05-17 2024-03-27 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
DE102021002748A1 (en) 2021-05-27 2022-12-01 Zellwerk Gmbh Process for the production of tumor-infiltrated T-lymphocytes (TIL) and their use as cell therapeutics for the treatment of human tumors
CA3223030A1 (en) * 2021-06-17 2022-12-22 CBio A/S Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
JP2024524185A (en) 2021-06-22 2024-07-05 アキレス セラピューティクス ユーケー リミテッド Methods for generating antigen-specific T cells
EP4373270A2 (en) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
EP4398915A1 (en) 2021-09-09 2024-07-17 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
US12377106B2 (en) 2021-10-26 2025-08-05 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
JP2024540106A (en) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Methods for culturing immune cells
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
CA3247928A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
JP2025504908A (en) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド Cytokine-associated tumor infiltrating lymphocyte compositions and methods
EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4507704A1 (en) * 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
JP2025531877A (en) 2022-09-09 2025-09-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Process for generating TIL products using PD-1/TIGIT TALEN double knockdown
US12181192B2 (en) * 2022-09-16 2024-12-31 Black & Decker, Inc. Methods and devices for controlling the temperature of a surface
CA3268005A1 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
JP2025537155A (en) 2022-11-04 2025-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド Methods for tumor infiltrating lymphocyte (TIL) expansion in conjunction with CD39/CD103 selection - Patent Application 20070122997
EP4623073A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
JP2025539816A (en) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド Two-dimensional process for the expansion of tumor-infiltrating lymphocytes and therapeutic methods therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
DE102023002417B3 (en) 2023-06-15 2024-12-05 Zellwerk Gmbh method for expanding cells
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
TW202509219A (en) 2023-07-13 2025-03-01 美商艾歐凡斯生物治療公司 Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038289A1 (en) * 2023-08-17 2025-02-20 H. Lee Moffitt Cancer Center And Research Institute Inc. Using 12 chemokine signature to select sting agonist and til treatments for solid tumors
WO2025047660A1 (en) * 2023-08-31 2025-03-06 国立大学法人筑波大学 Method for quantifying neoplastic follicular regulatory t cells and neoplastic follicular cytotoxic t cells, method for screening neoplastic follicular regulatory t cells and neoplastic follicular cytotoxic t cells, therapeutic composition, and kit
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
CN118710478B (en) * 2024-08-27 2025-01-03 福州大学 Passenger flow evacuation method for subway sudden operation interruption based on improved sparrow search algorithm

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2002036169A2 (en) 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US20040151704A1 (en) 2002-06-28 2004-08-05 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ITMI20022118A1 (en) 2002-10-04 2004-04-05 Abiogen Pharma Spa PROCEDURE FOR THE LARGE SCALE CULTURE OF T-LYMPHOCYTES IN A HOMOGENEOUS SYSTEM.
JP2007511205A (en) 2003-10-08 2007-05-10 ウィルソン ウォルフ マニュファクチャリング コーポレイション Method and apparatus for culturing cells using gas permeable substances
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (en) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
WO2007071409A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating colon cancer
CN101351546B (en) 2005-12-21 2013-05-29 江苏太瑞生诺生物医药科技有限公司 Method for treating disseminated cancer
WO2007071390A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
CA2634167C (en) 2005-12-21 2015-06-16 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
FR2911346B1 (en) * 2007-01-12 2012-12-07 Ct Hospitalier Universitaire De Nantes PROCESS FOR IN VITRO CULTURE OF T CELLS, PARTICULARLY T CELLS INFILTANT TUMORS SAID TIL
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
WO2009040789A2 (en) * 2007-09-24 2009-04-02 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
US20150320798A1 (en) 2012-11-27 2015-11-12 The Johns Hopkins University Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
EP2698430A3 (en) 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
KR20200070407A (en) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Conjugates of an il-2 moiety and a polymer
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN103502439B (en) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 Method for T cells with antigenic specificity propagation
US9315774B2 (en) * 2011-10-21 2016-04-19 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
CN102816734A (en) 2012-05-09 2012-12-12 阮润生 Method for obtaining tumor antigen-specific T cells
SG10202111564SA (en) 2012-05-18 2021-12-30 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
JP2015519080A (en) 2012-06-11 2015-07-09 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ Improved cell culture method for adoptive cell therapy
ES2862433T3 (en) 2012-11-27 2021-10-07 Ivan Marques Borrello Use of allogeneic bone marrow infiltrating lymphocytes treated with post-transplantation cyclophosphamide to increase antitumor immunity
ES2771251T3 (en) 2013-03-01 2020-07-06 Us Health Methods of producing enriched populations of tumor-reactive T cells from peripheral blood
AU2013379772B2 (en) 2013-03-01 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive T cells from tumor
AU2014302589B2 (en) 2013-06-24 2020-05-14 Wilson Wolf Manufacturing, LLC Closed system device and methods for gas permeable cell culture process
ES2773548T3 (en) * 2013-07-15 2020-07-13 Us Health Methods of preparing human papillomavirus anti-antigen T-cells
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
KR20250004905A (en) 2014-03-20 2025-01-08 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Tumor-infiltrating lymphocytes for adoptive cell therapy
ES2980788T3 (en) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
EP3838288A1 (en) 2014-06-11 2021-06-23 polybiocept GmbH Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
EP3155426B1 (en) 2014-06-13 2023-07-19 Immudex ApS General detection and isolation of specific cells by binding of labeled molecules
DK3188740T3 (en) 2014-09-04 2021-06-07 Univ Johns Hopkins ACTIVATION OF MARVIN FILTERING LYMPHOCYTES UNDER HYPOXIC CONDITIONS ALTERNATE TO NORMOXIC CONDITIONS
CA2963362A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
US10544392B2 (en) 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
FR3038324B1 (en) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement THERAPEUTIC-AIMED CELL CRYOPRESERVATION PROCESS
FR3040396A1 (en) 2015-06-30 2017-03-03 Chu Nantes PROCESS FOR CRYOPRESERVATION OF LYMPHOCYTES INFERATING THE TUMOR
WO2017048614A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
IL258935B2 (en) 2015-10-28 2024-08-01 Life Tech As Selective expansion of different T-cell subpopulations by altering cell surface signals and signal ratio
EP3487990A4 (en) 2016-06-28 2020-07-29 Geneius Biotechnology, Inc. T-CELL COMPOSITIONS FOR IMMUNOTHERAPY
CN106244538A (en) 2016-08-04 2016-12-21 英普乐孚生物技术(上海)有限公司 A kind of isolated culture method of the til cell in malignant ascite source
ES2837755T3 (en) 2016-09-14 2021-07-01 Abbvie Biotherapeutics Inc Anti-PD-1 antibodies
MX2019004707A (en) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc RE-STIMULATION OF CRYOCONSERVED INFILTRATING TUMOR LYMPHOCYTES.
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
KR102618948B1 (en) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. Residual tumor infiltrating lymphocytes and methods of making and using the same
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
CN106591232A (en) 2017-01-04 2017-04-26 安徽安龙基因医学检验所有限公司 Efficient PD-1-CD8+T cell culture method
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
KR102771581B1 (en) 2017-03-14 2025-02-25 주노 쎄러퓨티크스 인코퍼레이티드 Cryogenic storage method
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Operations for the production of tumor-infiltrating lymphocytes and their use in immunotherapy
CA3062874A1 (en) 2017-05-10 2018-11-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
CN107384867B (en) 2017-08-04 2020-09-11 北京世纪劲得生物技术有限公司 Preparation method of tumor tissue TIL cells and special culture medium
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

Also Published As

Publication number Publication date
US10130659B2 (en) 2018-11-20
US20250121009A1 (en) 2025-04-17
US10905718B2 (en) 2021-02-02
TWI799402B (en) 2023-04-21
US20210128621A1 (en) 2021-05-06
JP7169291B2 (en) 2022-11-10
US20200246384A1 (en) 2020-08-06
RS66452B1 (en) 2025-02-28
US20230012086A1 (en) 2023-01-12
US20200289569A1 (en) 2020-09-17
US10953047B2 (en) 2021-03-23
HUE070256T2 (en) 2025-05-28
US11007225B1 (en) 2021-05-18
JP7772680B2 (en) 2025-11-18
EP3766964A1 (en) 2021-01-20
KR102686794B1 (en) 2024-07-24
US11007226B2 (en) 2021-05-18
EP3730608A1 (en) 2020-10-28
US20220008469A1 (en) 2022-01-13
HRP20241688T1 (en) 2025-02-14
EP3722415A1 (en) 2020-10-14
FI3722415T3 (en) 2025-01-10
AU2025200434A1 (en) 2025-02-20
US20220387496A1 (en) 2022-12-08
SI3722415T1 (en) 2025-03-31
NZ758201A (en) 2024-01-26
US11304979B2 (en) 2022-04-19
MD3730608T2 (en) 2025-03-31
HRP20250068T1 (en) 2025-03-14
BR112019020326A2 (en) 2020-04-28
US12226434B2 (en) 2025-02-18
US20210100843A1 (en) 2021-04-08
CA3057975A1 (en) 2018-10-04
JP2021519582A (en) 2021-08-12
US11337998B2 (en) 2022-05-24
US11998568B2 (en) 2024-06-04
CR20190487A (en) 2020-03-17
DK3730608T3 (en) 2024-12-16
US20220387497A1 (en) 2022-12-08
PH12019502247A1 (en) 2020-06-29
CY1124136T1 (en) 2022-05-27
US10537595B2 (en) 2020-01-21
PT3601533T (en) 2021-05-24
US10953046B2 (en) 2021-03-23
RS61863B1 (en) 2021-06-30
JP2023011778A (en) 2023-01-24
EP3722415B1 (en) 2024-11-06
US20210128624A1 (en) 2021-05-06
US20220387494A1 (en) 2022-12-08
US10398734B2 (en) 2019-09-03
US20210106625A1 (en) 2021-04-15
US10653723B1 (en) 2020-05-19
US20220387499A1 (en) 2022-12-08
WO2018182817A1 (en) 2018-10-04
PT3730608T (en) 2025-01-07
US20180207201A1 (en) 2018-07-26
MA68598B1 (en) 2025-01-31
HRP20210677T1 (en) 2021-06-25
US11052116B2 (en) 2021-07-06
US20210207091A1 (en) 2021-07-08
FI3730608T3 (en) 2024-12-30
US11529372B1 (en) 2022-12-20
PL3722415T3 (en) 2025-03-31
US10272113B2 (en) 2019-04-30
US20190083538A1 (en) 2019-03-21
US20230133298A1 (en) 2023-05-04
CL2020002737A1 (en) 2021-03-05
US10463697B2 (en) 2019-11-05
TW201839129A (en) 2018-11-01
ES3009885T3 (en) 2025-03-31
US20220395533A1 (en) 2022-12-15
US20210128620A1 (en) 2021-05-06
CN110785486A (en) 2020-02-11
EP3730608B1 (en) 2024-10-23
US20210079348A1 (en) 2021-03-18
US10946045B2 (en) 2021-03-16
US20230015649A1 (en) 2023-01-19
US11168304B2 (en) 2021-11-09
JP2023012511A (en) 2023-01-25
LT3730608T (en) 2024-12-27
KR20240114787A (en) 2024-07-24
US20200281978A1 (en) 2020-09-10
US20210214685A1 (en) 2021-07-15
US20190358261A1 (en) 2019-11-28
SI3730608T1 (en) 2025-03-31
US11052115B2 (en) 2021-07-06
US20220378838A1 (en) 2022-12-01
US12121541B2 (en) 2024-10-22
US10946044B2 (en) 2021-03-16
US20190083539A1 (en) 2019-03-21
MD3722415T2 (en) 2025-05-31
US20200155601A1 (en) 2020-05-21
US11291687B2 (en) 2022-04-05
US20210353677A1 (en) 2021-11-18
ES3008832T3 (en) 2025-03-25
US20200306307A1 (en) 2020-10-01
EP3910055A1 (en) 2021-11-17
EP3601533B1 (en) 2021-02-24
US20210128623A1 (en) 2021-05-06
JP2020515257A (en) 2020-05-28
US20190000883A1 (en) 2019-01-03
MA68856B1 (en) 2025-01-31
US20210100842A1 (en) 2021-04-08
IL269543A (en) 2019-11-28
US11083752B2 (en) 2021-08-10
LT3722415T (en) 2025-01-10
MD3601533T2 (en) 2021-07-31
US10363273B2 (en) 2019-07-30
US12485145B2 (en) 2025-12-02
US11040070B2 (en) 2021-06-22
SI3601533T1 (en) 2021-09-30
US20220000924A1 (en) 2022-01-06
AU2018243355A1 (en) 2019-10-31
US20210137984A1 (en) 2021-05-13
PE20191841A1 (en) 2019-12-31
US20190358259A1 (en) 2019-11-28
CL2019002769A1 (en) 2020-05-08
DK3722415T3 (en) 2025-01-13
EP4279574A3 (en) 2024-04-10
US20220000925A1 (en) 2022-01-06
ES2874335T3 (en) 2021-11-04
US11202804B2 (en) 2021-12-21
US20210379111A1 (en) 2021-12-09
US20180282694A1 (en) 2018-10-04
US20210207092A1 (en) 2021-07-08
LT3601533T (en) 2021-06-10
CO2019011995A2 (en) 2020-02-18
US20190070222A1 (en) 2019-03-07
IL305198A (en) 2023-10-01
US12194061B2 (en) 2025-01-14
US10420799B2 (en) 2019-09-24
US20180325954A1 (en) 2018-11-15
US10166257B2 (en) 2019-01-01
US20190000882A1 (en) 2019-01-03
US20210128625A1 (en) 2021-05-06
US20220000923A1 (en) 2022-01-06
PT3722415T (en) 2025-01-08
EP3601533A1 (en) 2020-02-05
ECSP19077884A (en) 2020-01-31
US10918666B2 (en) 2021-02-16
US20250121008A1 (en) 2025-04-17
US10646517B2 (en) 2020-05-12
SMT202100298T1 (en) 2021-07-12
KR20190142342A (en) 2019-12-26
US20190358260A1 (en) 2019-11-28
US20210361713A1 (en) 2021-11-25
US11344579B2 (en) 2022-05-31
US10925900B2 (en) 2021-02-23
US20250082683A1 (en) 2025-03-13
JP7522037B2 (en) 2024-07-24
US20230045899A1 (en) 2023-02-16
JOP20190224A1 (en) 2019-09-26
PL3601533T3 (en) 2021-08-16
HUE070176T2 (en) 2025-05-28
SMT202500040T1 (en) 2025-03-12
HUE054829T2 (en) 2021-10-28
US20200306306A1 (en) 2020-10-01
US11517592B1 (en) 2022-12-06
US10695372B2 (en) 2020-06-30
AU2018243355B2 (en) 2024-10-24
PL3730608T3 (en) 2025-03-31
US11273181B2 (en) 2022-03-15
US11013770B1 (en) 2021-05-25
SMT202500027T1 (en) 2025-03-12
US20220362301A1 (en) 2022-11-17
US11273180B2 (en) 2022-03-15
US11541077B2 (en) 2023-01-03
US10639330B2 (en) 2020-05-05
US20210128622A1 (en) 2021-05-06
US11168303B2 (en) 2021-11-09
US10894063B2 (en) 2021-01-19
MX2024002827A (en) 2024-03-19
US20220387495A1 (en) 2022-12-08
JP2025023951A (en) 2025-02-19
US20190083536A1 (en) 2019-03-21
US20200276241A1 (en) 2020-09-03
MX2019011768A (en) 2019-12-09
US20180280436A1 (en) 2018-10-04
EP4279574A2 (en) 2023-11-22
JP2023012510A (en) 2023-01-25
US20210361712A1 (en) 2021-11-25
US20220387498A1 (en) 2022-12-08
RS66400B1 (en) 2025-02-28
US11202803B1 (en) 2021-12-21
US11241456B2 (en) 2022-02-08
US20200276242A1 (en) 2020-09-03
DK3601533T3 (en) 2021-05-03
TN2019000273A1 (en) 2021-01-07
US10933094B2 (en) 2021-03-02

Similar Documents

Publication Publication Date Title
SG11201908994RA (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201804363UA (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201907056XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201811432WA (en) Rna for cancer therapy
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201809751XA (en) Egfr inhibitor compounds
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201804395PA (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases